| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies (NCT04383938) | Aprea Therapeutics | 2020-06-25 |
| Study of Poziotinib in Japanese Patients With NSCLC (NCT04402008) | Spectrum Pharmaceuticals, Inc | 2020-06-23 |
| Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor (NCT04545632) | Boryung Pharmaceutical Co., Ltd | 2020-06-10 |
| Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) (NCT04367311) | Nasser Hanna | 2020-05-22 |
| Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC (NCT03990077) | Shanghai Kechow Pharma, Inc. | 2020-05-21 |
| Lymphadenectomy in NSCLC With and Without Adjuvant Therapy (NCT04419935) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-05-13 |
| Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (NCT04392505) | Oslo University Hospital | 2020-05-11 |
| A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation (NCT04204473) | TYK Medicines, Inc | 2020-05-07 |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (NCT04223596) | Fundación GECP | 2020-05-04 |
| Lorlatinib Combinations in Lung Cancer (NCT04292119) | Massachusetts General Hospital | 2020-05-01 |
| Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC (NCT04405661) | Guangzhou Institute of Respiratory Disease | 2020-04-28 |
| A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors (NCT05602792) | ImmVira Pharma Co. Ltd | 2020-04-21 |
| A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors (NCT04413227) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2020-04-02 |
| Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy (NCT04741633) | Fudan University | 2020-04-01 |
| Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study (NCT04313660) | Xiaorong Dong | 2020-04-01 |
| Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy (NCT04333004) | Xiaorong Dong | 2020-04-01 |
| Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping (NCT04318938) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-03-30 |
| Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer (NCT04252365) | Guangdong Association of Clinical Trials | 2020-03-01 |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (NCT04328844) | iOnctura | 2020-02-25 |
| Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response (NCT04146064) | University Health Network, Toronto | 2020-02-24 |
| Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy (NCT04930133) | Seoul St. Mary's Hospital | 2020-02-24 |
| A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC (NCT04807114) | Universitaire Ziekenhuizen KU Leuven | 2020-02-01 |
| Whether Sputum Can Serve as an Alternative Source for Liquid Biopsy in Patients With Lung Cancer (NCT05034445) | Guangzhou Institute of Respiratory Disease | 2020-01-30 |
| EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer (NCT04159025) | Washington University School of Medicine | 2020-01-08 |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer (NCT04077099) | Regeneron Pharmaceuticals | 2020-01-07 |
| Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy (NCT07243899) | Shanghai Zhongshan Hospital | 2020-01-01 |
| A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711 (NCT04135820) | Beta Pharma, Inc. | 2019-12-17 |
| A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711 (NCT04135833) | Beta Pharma, Inc. | 2019-12-12 |
| Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer (NCT04199559) | Henan Cancer Hospital | 2019-12-01 |
| To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects (NCT04032821) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-11-20 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC (NCT04069936) | WindMIL Therapeutics | 2019-10-15 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer (NCT04553601) | The First Affiliated Hospital of Xiamen University | 2019-10-01 |
| Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03986528) | Jie Li | 2019-08-28 |
| Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer (NCT03999710) | Memorial Sloan Kettering Cancer Center | 2019-07-19 |
| A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC) (NCT04871997) | Qian Chu | 2019-07-12 |
| A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive (NCT03812809) | Beta Pharma Shanghai | 2019-07-05 |
| Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI (NCT04007835) | Guangdong Association of Clinical Trials | 2019-07-01 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (NCT03965845) | Calithera Biosciences, Inc | 2019-06-25 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (NCT03689855) | Washington University School of Medicine | 2019-06-05 |
| Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) (NCT03810066) | University Hospital, Essen | 2019-06-03 |
| LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer (NCT06778512) | The First Affiliated Hospital of Guangzhou Medical University | 2019-06-01 |
| Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer (NCT03166254) | Washington University School of Medicine | 2019-04-30 |
| Coagulation System In STereotactic Radiotherapy Of NSCLC (NCT03893461) | Odense University Hospital | 2019-03-26 |
| FGFR Inhibitor in FGFR Dysregulated Cancer (NCT03827850) | Lung Cancer Group Cologne | 2019-03-25 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer (NCT03794544) | MedImmune LLC | 2019-03-08 |
| Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (NCT03799601) | Tongji Hospital | 2019-03-01 |
| Detecting Lung Cancer Based on Exhaled Breath (NCT04419207) | Peking University People's Hospital | 2019-03-01 |
| D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer (NCT03861156) | InventisBio Co., Ltd | 2019-02-28 |
| Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (NCT03625323) | Immutep S.A.S. | 2019-02-21 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (NCT03808662) | Memorial Sloan Kettering Cancer Center | 2019-01-16 |
| Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations (NCT05701787) | Shanghai Chest Hospital | 2019-01-01 |
| Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients (NCT05688046) | Suzhou Municipal Hospital | 2019-01-01 |
| First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy (NCT03798535) | AstraZeneca | 2018-12-19 |
| A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI (NCT03058094) | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2018-12-01 |
| A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (NCT02905591) | Joseph J. Cullen, MD, FACS | 2018-11-16 |
| Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC (NCT03535363) | Case Comprehensive Cancer Center | 2018-10-26 |
| A Registry to Evaluate the Performance of the BDX-XL2 Test (NCT03766958) | Biodesix, Inc. | 2018-10-16 |
| A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib (NCT03744715) | Spectrum Pharmaceuticals, Inc | 2018-10-11 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma (NCT03656393) | Shenzhen People's Hospital | 2018-08-31 |
| IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC (NCT03562871) | IO Biotech | 2018-08-22 |
| Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer). (NCT03634826) | Peking University People's Hospital | 2018-08-15 |
| Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC (NCT03636685) | Chinese Academy of Medical Sciences | 2018-08-15 |
| A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations (NCT03634059) | Hebei Medical University Fourth Hospital | 2018-08-15 |
| A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC (NCT03601598) | Harbin Medical University | 2018-07-30 |
| The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy (NCT04670107) | The Affiliated Hospital of Qingdao University | 2018-06-01 |
| A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC (NCT03546452) | Shanghai Chest Hospital | 2018-05-18 |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (NCT03526835) | Merus B.V. | 2018-05-02 |
| A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (NCT03513666) | Shanghai Junshi Bioscience Co., Ltd. | 2018-04-09 |
| 18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy (NCT03741231) | University Hospital, Brest | 2018-03-01 |
| Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients (NCT03453307) | K2 Oncology, Inc. | 2018-01-30 |
| Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (NCT03428022) | Shenzhen People's Hospital | 2017-12-01 |
| Stereotactic Body Radiotherapy for the Treatment of OPD (NCT03256981) | Institute of Cancer Research, United Kingdom | 2017-11-27 |
| Intervention of Engineered Immune Effector T Cells Against Lung Cancer (NCT03353428) | Shenzhen Geno-Immune Medical Institute | 2017-11-15 |
| A Study of BCD-135 in Patients With Advanced Solid Tumors (NCT03464032) | Biocad | 2017-10-31 |
| ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS (NCT03465241) | Sun Yat-sen University | 2017-10-21 |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation (NCT03318939) | Spectrum Pharmaceuticals, Inc | 2017-10-11 |
| Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) (NCT02856893) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-10-10 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224) | Apollomics Inc. | 2017-09-27 |
| The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001 (NCT03301688) | Shanghai Junshi Bioscience Co., Ltd. | 2017-09-18 |
| TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy (NCT03394118) | Asan Medical Center | 2017-08-11 |
| A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer (NCT03246854) | National Health Research Institutes, Taiwan | 2017-07-18 |
| Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy (NCT02869685) | Xinqiao Hospital of Chongqing | 2017-07-01 |
| Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer (NCT02898116) | Ludwig Institute for Cancer Research | 2017-05-10 |
| Echocardiography for RILI Prediction (NCT02501707) | Maastricht Radiation Oncology | 2017-04-25 |
| Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer (NCT04858204) | University Hospital, Brest | 2017-04-14 |
| The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum. (NCT03073902) | Xinqiao Hospital of Chongqing | 2017-03-25 |
| Descriptive Observational Study ALK-2016-CPHG (NCT03718117) | Pfizer | 2017-01-03 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer (NCT02973763) | Allist Pharmaceuticals, Inc. | 2016-12-30 |
| Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (NCT06207292) | Radiotherapy Oncology Centre "Santa Maria" Hospital | 2016-12-01 |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) (NCT02973789) | NovoCure GmbH | 2016-12-01 |
| A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer (NCT02976116) | Hutchison Medipharma Limited | 2016-12-01 |
| Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) (NCT03416231) | Affiliated Hospital of North Sichuan Medical College | 2016-11-30 |
| Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC (NCT02954172) | Innovent Biologics (Suzhou) Co. Ltd. | 2016-11-28 |
| SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations (NCT02940990) | Shanghai Chest Hospital | 2016-11-01 |